UPDATE: The Medicines Co. Reminds Investors of FDA CRDAC Meeting Today, Says Proposing Cangrelor Be Indicated to Maintain P2Y12 Inhibition

The Medicines Company (NASDAQ: MDCO ) announced today that NASDAQ has halted trading of the company's stock. The U.S. Food and Drug Administration's (FDA) Cardiovascular and Renal Drugs Advisory Committee (CRDAC) is meeting today to discuss the new drug application (NDA) for cangrelor injection, for the proposed indication of reduction of thrombotic cardiovascular events including